These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 32609649)

  • 1. Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients.
    Xhakaza L; Abrahams-October Z; Pearce B; Masilela CM; Adeniyi OV; Johnson R; Ongole JJ; Benjeddou M
    Drug Metab Pers Ther; 2020 Jun; ():. PubMed ID: 32609649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients.
    Xhakaza L; Abrahams-October Z; Pearce B; Masilela CM; Adeniyi OV; Johnson R; Ongole JJ; Benjeddou M
    Drug Metab Pers Ther; 2020 Jun; 35(2):. PubMed ID: 32681778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of
    Chen P; Cao Y; Chen S; Liu Z; Chen S; Guo Y
    Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of effect of the SLC47A1 and SLC47A2 gene polymorphisms on the glycemic response to metformin in type 2 diabetes mellitus patients.
    Raj GM; Mathaiyan J; Wyawahare M; Priyadarshini R
    Drug Metab Pers Ther; 2018 Dec; 33(4):175-185. PubMed ID: 30433870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Association of Solute Carrier Transporter Gene Variants with Metformin Response.
    Abrahams-October Z; Xhakaza L; Pearce B; Mandisa Masilela C; Benjeddou M; Vincent Adeniyi O; Johnson R; Jebio Ongole J
    Balkan J Med Genet; 2021 Jun; 24(1):47-56. PubMed ID: 34447659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes.
    Phani NM; Vohra M; Kakar A; Adhikari P; Nagri SK; D'Souza SC; Umakanth S; Satyamoorthy K; Rai PS
    Pharmacogenomics; 2018 Jul; 19(11):905-911. PubMed ID: 29914345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes: A systematic review.
    Mofo Mato EP; Guewo-Fokeng M; Essop MF; Owira PMO
    Medicine (Baltimore); 2018 Jul; 97(27):e11349. PubMed ID: 29979413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus.
    Pérez-Gómez N; Fernández-Ortega MD; Elizari-Roncal M; Santos-Mazo E; la Maza-Pereg L; Calvo S; Alcaraz R; Sanz-Solas A; Vinuesa R; Saiz-Rodríguez M
    Pharmacogenomics; 2023 Aug; 24(12):651-663. PubMed ID: 37610884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population diversity of three variants of the SLC47A2 gene (MATE2-K transporter) in Mexican Mestizos and Native Americans.
    Favela-Mendoza AF; Fricke-Galindo I; Cuevas-Sánchez WF; Aguilar-Velázquez JA; Martínez-Cortés G; Rangel-Villalobos H
    Mol Biol Rep; 2021 Sep; 48(9):6343-6348. PubMed ID: 34383246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between organic cation transporter genetic polymorphisms and metformin response and intolerance in T2DM individuals: a systematic review and meta-analysis.
    Peng A; Gong C; Xu Y; Liang X; Chen X; Hong W; Yan J
    Front Public Health; 2023; 11():1183879. PubMed ID: 37546319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of SLC22A3 rs543159 and rs1317652 genetic variants on metformin therapeutic efficacy in newly diagnosed patients with type 2 diabetes mellitus: 25 weeks follow-up study.
    Taheri R; Kazerouni F; Mirfakhraei R; Kalbasi S; Shahrokhi SZ; Rahimipour A
    Gene; 2022 May; 823():146382. PubMed ID: 35240257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic Evaluation of Metformin and Sulphonylurea Response in Mexican Mestizos with Type 2 Diabetes.
    Marta M; Sánchez-Pozos K; Jaimes-Santoyo J; Monroy-Escutia J; Rivera-Santiago C; de Los Ángeles Granados-Silvestre M; Ortiz-López MG
    Curr Drug Metab; 2020; 21(4):291-300. PubMed ID: 32407269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of TCF7L2 rs7903146 variant on metformin response in patients with type 2 diabetes.
    Dujic T; Bego T; Malenica M; Velija-Asimi Z; Ahlqvist E; Groop L; Pearson ER; Causevic A; Semiz S
    Bosn J Basic Med Sci; 2019 Nov; 19(4):368-374. PubMed ID: 31070566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy.
    Rajpathak SN; Rajgopalan S; Engel SS
    J Diabetes Complications; 2014; 28(6):831-5. PubMed ID: 25104238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single Nucleotide Polymorphisms Associated with Metformin and Sulphonylureas' Glycaemic Response among South African Adults with Type 2 Diabetes Mellitus.
    Masilela C; Pearce B; Ongole JJ; Adeniyi OV; Benjeddou M
    J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33561991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin Pharmacogenetics: Effects of SLC22A1, SLC22A2, and SLC22A3 Polymorphisms on Glycemic Control and HbA1c Levels.
    Al-Eitan LN; Almomani BA; Nassar AM; Elsaqa BZ; Saadeh NA
    J Pers Med; 2019 Mar; 9(1):. PubMed ID: 30934600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of ATM and SLC22A1 Polymorphisms on Therapeutic Response to Metformin in Iranian Diabetic Patients.
    Shokri F; Ghaedi H; Ghafouri Fard S; Movafagh A; Abediankenari S; Mahrooz A; Kashi Z; Omrani MD
    Int J Mol Cell Med; 2016; 5(1):1-7. PubMed ID: 27386433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin transporter pharmacogenomics: insights into drug disposition-where are we now?
    Chan P; Shao L; Tomlinson B; Zhang Y; Liu ZM
    Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1149-1159. PubMed ID: 30375241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The study to understand the genetics of the acute response to metformin and glipizide in humans (SUGAR-MGH): design of a pharmacogenetic resource for type 2 diabetes.
    Walford GA; Colomo N; Todd JN; Billings LK; Fernandez M; Chamarthi B; Warner AS; Davis J; Littleton KR; Hernandez AM; Fanelli RR; Lanier A; Barbato C; Ackerman RJ; Khan SQ; Bui R; Garber L; Stolerman ES; Moore AF; Huang C; Kaur V; Harden M; Taylor A; Chen L; Manning AK; Huang P; Wexler D; McCarthy RM; Lo J; Thomas MK; Grant RW; Goldfine A; Hudson MS; Florez JC
    PLoS One; 2015; 10(3):e0121553. PubMed ID: 25812009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered Glycemic Control Associated With Polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican Population With Type 2 Diabetes Mellitus Treated With Metformin: A Cohort Study.
    Reséndiz-Abarca CA; Flores-Alfaro E; Suárez-Sánchez F; Cruz M; Valladares-Salgado A; Del Carmen Alarcón-Romero L; Vázquez-Moreno MA; Wacher-Rodarte NA; Gómez-Zamudio JH
    J Clin Pharmacol; 2019 Oct; 59(10):1384-1390. PubMed ID: 31012983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.